NOXOPHARM-LIMITED
25.8.2021 14:37:12 CEST | Business Wire | Press release
Australian clinical-stage drug development company Noxopharm (ASX:NOX) has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil (Veyonda® ), a TBK1 (TANK-binding kinase 1) inhibitor, as an anti-inflammatory in patients with moderate COVID-19 disease. Based on initial positive results, Noxopharm has started discussions to add Veyonda to one of the global clinical trial programs looking at identifying effective anti-inflammatory therapies in COVID-19 disease.
The relevance of blocking TBK1 is seen as important in two respects: (i) ability to block a dysfunctional immune response to RNA viruses such as coronavirus and influenza virus; (ii) potential to avoid the adverse immune-suppressing effects of standard anti-inflammatory drugs such as prednisone and dexamethasone in potentially slowing viral clearance and increasing the risk of secondary infections.
“The NOXCOVID Phase I clinical trial is highly encouraging for Veyonda in this role as a high proportion of the patients were experiencing elevated inflammation,” said Noxopharm CEO and Managing Director Graham Kelly . “In this trial, no major safety issues were identified and 37 of 38 patients hospitalized with moderate respiratory disease recovered.”
“Based on what is known today, Veyonda’s properties give it the potential to address a gap in our armory of COVID-19 therapeutics,” said Marcel Nold , M.D., professor of pediatric immunology at Monash University and the Hudson Institute and pediatrician at Monash Children’s Hospital. “Patients can self-administer, allowing its use in their own home. Its mechanism of action may enable treatment of moderately ill COVID-19 patients and, importantly, it could also be effective against many other viruses. In Veyonda, Noxopharm has an exciting opportunity at hand.”
About Noxopharm
Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine storm (septic shock).
Veyonda® is the Company’s first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immunomodulatory functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiation therapies and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, as well as contributing to an anti-cancer action, but also potentially blocking septic shock.
Noxopharm is running comprehensive drug discovery programs in both oncology and inflammation, and is the major shareholder of US biotechnology company, Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005462/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carbon Measures Opens Singapore Office and Launches First In-Country Pilot to Advance Industrial Decarbonization in Hard-to-Abate Sectors12.11.2026 12:00:00 CET | Press release
Today, at COP31, Carbon Measures announced the establishment of its Singapore office, with support from the Singapore Economic Development Board (EDB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112827071/en/ Carbon Measures opens Singapore office and launches first in-country pilot to advance industrial decarbonization in hard-to-abate sectors. The Singapore office will serve as Carbon Measures’ Asia-Pacific hub, expanding its technical expertise and knowledge capabilities while strengthening engagement with key stakeholders across the region. The office will focus on advancing industrial decarbonization policies for hard-to-abate sectors, convening companies, nonprofit organizations, academic institutions and other partners to guide the Pilot’s development and implementation. “We welcome Carbon Measures’ establishment of its first office in the region. By piloting new approaches for product-level carbon accounting,
Focused Support Delivers Link 16 to Royal Netherlands Air and Space Force MQ-9 Fleet With Cavok STRIKE12.11.2026 12:00:00 CET | Press release
Focused Support LLC today announced the successful deployment of Cavok® STRIKE to the Royal Netherlands Air and Space Force (RNLASF), providing its MQ-9 fleet with enhanced Link 16 participation capabilities without requiring modifications to the aircraft. The deployment represents a significant advance in integrating remotely piloted aircraft into the shared tactical picture, improving situational awareness, interoperability, and coordination across joint and coalition forces. The installation marks a key milestone for Focused Support as Cavok STRIKE expands into European military operations. Integrated within the Cavok Mission Ecosystem, STRIKE addresses a persistent tactical challenge: extending Link 16 to non-traditional participants without costly or complex aircraft modifications. Focused Support Founder and CEO, Jonathan Shill, remarked, “Two decades ago we asked for Link 16 on the MQ-1 Predator but were denied because the 8 lb. terminal represented a half hour of time on statio
Ahead of Frieze Abu Dhabi, 421 Arts Campus Spotlights Emerging Artistic Practices12.11.2026 11:15:00 CET | Press release
As Abu Dhabi prepares to welcome the international art community for the inaugural Frieze Abu Dhabi this November, 421 Arts Campus presents two exhibitions highlighting artistic experimentation, research, and emerging creative practices in the UAE and wider region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112518634/en/ Juma Alhaj, Revelation, 2026 at 421 Arts Campus. Courtesy of 421 and the artist. (Photography by: Ismail Noor, Seeing Things) On view until 10 January 2027, the exhibitions bring together distinct artistic approaches, from Juma Alhaj’s exploration of reflection and self-discovery to an examination of how knowledge is formed and shared through informal modes of communication. Revelation, the first institutional solo exhibition by Emirati artist Juma Alhaj, marks a significant evolution in his practice. Grounded in reading, journaling, and philosophical inquiry, the exhibition explores reflection, solit
a2z Radiology AI Receives EU MDR Certification for AI That Detects 182 Findings Across Head, Chest, Abdomen and Pelvis CT12.11.2026 09:00:00 CET | Press release
a2z-Drafter is the first AI product certified under the EU Medical Device Regulation to support both detection and report drafting across head, chest, abdomen and pelvis CT. a2z Radiology AI Inc. today announced that a2z-Drafter has been certified under the EU Medical Device Regulation (MDR). The software supports triage, detection and report drafting on CT scans of the head, chest, abdomen and/or pelvis. “Radiology teams have had to piece together separate AI tools for each condition and body region,” said Samir Rajpurkar, co-founder and CEO of a2z Radiology AI. “a2z-Drafter is one product that works on head, chest and abdomen-pelvis CT scans and gives the radiologist a structured starting point for the report. This certification lets us bring that to radiology teams in the European Union.” a2z-Drafter detects 182 validated radiological findings on CT studies of the head, chest, abdomen and/or pelvis, with supplementary attributes for selected findings. The findings span acute conditi
KiddeFenwal Secures A2P System Certification from Centre National de Prévention et de Protection in France12.11.2026 09:00:00 CET | Press release
Assurance Prévention Protection benchmark from CNPP marks key milestone in the global adoption of NATURA™ inert gas fire suppression system.Certification elevates proven technology that conserves water while safeguarding assets and minimizing downtime. KiddeFenwal, the global leader in fire protection and safety controls, has received an Assurance Prévention Protection (A2P) System Certification for its NATURA™ inert gas fire suppression system. The designation from France’s Centre National de Prévention et de Protection (CNPP), one of the most respected fire safety testing and certification organizations in Europe, illustrates how KiddeFenwal is expanding the reach of its industry-leading technologies throughout the world with the support of independent, third-party evaluators. “KiddeFenwal is grateful to CNPP for standing behind our proven NATURA™ system,” said Rekha Agrawal, CEO of KiddeFenwal. “The certification enables our systems to protect the facilities and institutions that ma
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom